文献速递肺栓塞与肺血管病

推进心脏磁共振在肺动脉高压风险分层中的实施

Toward the Implementation of Optimal Cardiac Magnetic Resonance Risk Stratification in Pulmonary Arterial Hypertension.
PubMed 文献 · Chest · 2023-07-30

该研究在258例初治肺动脉高压患者中验证2022年ESC/ERS指南提出的心脏磁共振三分类风险阈值的预后区分能力。基线时多数患者被分入中危组,风险组间生存区分度差;首次再评估时区分度适当。结论提示现行CMR切点需调整,随访评估更能反映个体治疗反应。

要点

  • 基线时CMR三分类风险组间生存区分度差,随访再评估时区分度适当。
  • 现行ESC/ERS 2022指南CMR切点多源于单中心,需外部验证与调整。
  • 随访CMR风险分层有助于评估个体治疗反应。

核心结论

  • 现行ESC/ERS 2022肺动脉高压指南提出的CMR风险切点需调整,因缺乏后处理共识且普遍适用性有限。
  • 随访时进行风险评分的生存区分度优于基线,强调个体治疗反应的重要性。

研究设计与样本

  • 研究分析了荷兰阿姆斯特丹大学医学中心(Vrije Universiteit)2001至2022年诊断的258例初治、未治疗肺动脉高压患者。
  • 其中172例在3个月至1.5年后有随访CMR影像。
  • 在基线和首次再评估时,使用指南变量(右心室射血分数、右心室收缩末期容积指数、左心室每搏量指数)检验CMR三风险分层的区分能力。

主要发现

  • 根据CMR三风险分层,诊断时大多数患者为中危(n=115,45%)。
  • 低危患者仅29例(11%),高危患者114例(44%)。
  • 基线时风险组间生存区分度差,首次再评估时生存区分度适当。

关键数值与推荐

  • 2022年ESC/ERS肺动脉高压指南将CMR指标纳入PAH风险分层,引入识别估计1年死亡风险<5%、5%至20%和>20%的阈值。
  • 本研究使用右心室射血分数、右心室收缩末期容积指数和左心室每搏量指数进行风险分层。

临床怎么用

  • 临床采用现行CMR切点进行PAH风险分层时需谨慎,尤其基线评估。
  • 随访CMR风险再评估可能更有助于判断治疗反应和预后。

局限性

  • CMR切点多基于单中心数据,需外部验证。
  • 后处理共识缺乏,限制普遍适用性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The 2022 European Society of Cardiology/European Respiratory Society pulmonary hypertension (PH) guidelines incorporate cardiac magnetic resonance (CMR) imaging metrics in the risk stratification of patients with pulmonary arterial hypertension (PAH). Thresholds to identify patients at estimated 1-year mortality risks of < 5%, 5% to 20%, and > 20% are introduced. However, these cutoff values are mostly single center-based and require external validation. RESEARCH QUESTION: What are the discriminative prognostic properties of the current CMR risk thresholds stratifying patients with PAH? STUDY DESIGN AND METHODS: We analyzed data from incident, treatment-naïve patients with PAH from the Amsterdam University Medical Centres, Vrije Universiteit, The Netherlands. The discriminative properties of the proposed CMR three risk strata were tested at baseline and first reassessment, using the following PH guideline variables: right ventricular ejection fraction, indexed right ventricular end-systolic volume, and indexed left ventricular stroke volume. RESULTS: A total of 258 patients with PAH diagnosed between 2001 and 2022 fulfilled the study criteria and were included in this study. Of these, 172 had follow-up CMR imaging after 3 months to 1.5 years. According to the CMR three risk strata, most patients were classified at intermediate risk (n = 115 [45%]) upon diagnosis. Only 29 (11%) of patients with PAH were classified at low risk, and 114 (44%) were classified at high risk. Poor survival discrimination was seen between risk groups. Appropriate survival discrimination was seen at first reassessment. INTERPRETATION: Risk stratifying patients with PAH with the recent proposed CMR cutoffs from the European Society of Cardiology/European Respiratory Society 2022 PH guidelines requires adjustment because post-processing consensus is lacking and general applicability is limited. Risk assessment at follow-up yielded better survival discrimination, emphasizing the importance of the individual treatment response.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Celant LR, Wessels JN, Marcus JT, et al. Toward the Implementation of Optimal Cardiac Magnetic Resonance Risk Stratification in Pulmonary Arterial Hypertension. Chest. 2023. PMID: 37527773. doi:10.1016/j.chest.2023.07.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。